<?xml version="1.0" encoding="UTF-8"?>
<p id="p0155">
 <italic>INO-4800</italic> from Inovio is a DNA plasmid vaccine. The company has experience with such platforms with candidate vaccines for MERS and SARS. The vaccine needs a delivery system through electroporation, which shall add to the cost of the vaccine. Phase I trial using 2 doses spaced 4 weeks apart has been completed, and results shall be available in June 2020. Inovio is planning to start phase II-III trials soon.
 <xref rid="bib81" ref-type="bibr">
  <sup>81</sup>
 </xref>
</p>
